Prevalence of Liver Steatosis Among Workers in Ouagadougou and Associated Factors: A Cross-Sectional Study.

Aims: Liver steatosis prevalence is growing, linked to the current worldwide epidemics of obesity and Type 2 diabetes. In sub-Saharan Africa, data on apparent healthy workers must still be included. This study aimed to determine the prevalence of hepatic steatosis and its associated factors in the workplace.

Immune response to GeneVac-B (rDNA I.P. hepatitis B vaccine) in vaccinated persons with a standard schedule in Bobo-Dioulasso, Burkina Faso.

Objective: This study aimed to evaluate the immune response in people fully vaccinated against hepatitis B with the GeneVac-B vaccine in Burkina Faso under actual conditions of use.

Methods: This cross-sectional study included individuals fully vaccinated with GeneVac-B. For each consenting participant, sociodemographic and clinical data were collected using a structured questionnaire.

Mass screening of hepatitis B and C in Burkina Faso: seroprevalence update and impact of hepatitis B vaccine.

Introduction: Updated data on the seroprevalences of hepatitis B and C viruses (HBV, HCV) are required to enable the adaptation of control strategies. In this study, we aimed to: (i) estimate the seroprevalences of HBsAg carriers and HCV exposure in the general population, and (ii) determine the impact of vaccination on HBV circulation since its introduction in 2006 in the Expanded Program on Immunization (EPI).

Methodology: From October 2020 to October 2022, a mass screening campaign was conducted in 10 cities across Burkina Faso.

Evaluation of the Diagnostic Performances of the SD-BiolineHBeAg Rapid Test Used Routinely for the Management of HBV-Infected Individuals in Burkina Faso.

Hepatitis B e antigen (HBeAg) is a marker of wild-type hepatitis B virus replication. In resource-limited countries where access to enzyme-linked immunosorbent assay (ELISA) remains a challenge, rapid diagnostic tests (RDT) constitute a good alternative. The HBeAg status is employed to evaluate eligibility for antiviral therapy and to prevent the transmission of hepatitis B from mother to child (PMTCT).